2012 ASCO:FIH phase I study-results of HSP90 inhibitor AT13387 in refractory solid tumors

2012 ASCO:FIH phase I study-results of HSP90 inhibitor AT13387 in refractory solid tumors

2012 AACR: AT13387, HSP90 inhibitor effective in vemurafenib-sensitive and -resistant melanoma model

2012 AACR: AT13387, HSP90 inhibitor effective in vemurafenib-sensitive and -resistant melanoma model

2012 Thoracic Symposium: HSP90 Inhibitor AT13387 Effective in Mutant EGFR and ALK-Positive NSCLC

2012 Thoracic Symposium: HSP90 Inhibitor AT13387 Effective in Mutant EGFR and ALK-Positive NSCLC